It's Showtime for Pacira Pharmaceuticals
Pacira Pharmaceuticals (NAS: PCRX) is expected to report Q2 earnings on Aug. 9. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Pacira Pharmaceuticals' revenues will increase 141.1% and EPS will remain in the red.
The average estimate for revenue is $8.8 million. On the bottom line, the average EPS estimate is -$0.52.
Last quarter, Pacira Pharmaceuticals chalked up revenue of $7.8 million. GAAP reported sales were much higher than the prior-year quarter's $3.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.47. GAAP EPS were -$0.47 for Q1 versus -$0.98 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 16.8%, 1,170 basis points better than the prior-year quarter. Operating margin was -142.7%, 4,170 basis points better than the prior-year quarter. Net margin was -152.4%, 10,060 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $41.0 million. The average EPS estimate is -$1.54.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 17 members out of 26 rating the stock outperform, and nine members rating it underperform. Among nine CAPS All-Star picks (recommendations by the highest-ranked CAPS members), four give Pacira Pharmaceuticals a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pacira Pharmaceuticals is buy, with an average price target of $16.20.
Over the decades, small-cap stocks, like Pacira Pharmaceuticals have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Pacira Pharmaceuticals to My Watchlist.
The article It's Showtime for Pacira Pharmaceuticals originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.